Advancing pluripotent stem cell technologies for modelling haematopoietic stem cell
development and blood therapies requires identifying key regulators of haematopoietic …

Current sources of platelets for transfusion are insufficient and associated with risk of
alloimmunization and blood-borne infection. These limitations could be addressed by the …

Megakaryocytopoiesis and thrombocytopoiesis result from the interactions between
hematopoietic progenitor cells, humoral factors, and marrow stromal cells derived from …

Platelets are released from terminally differentiated megakaryocytes (MKs) through lineage
commitment, although the underlying mechanisms of megakaryopoiesis and subsequent …

Background Refinement of therapeutic-scale platelet production in vitro will provide a new
source for transfusion in patients undergoing chemotherapy or radiotherapy. However …

To improve the recapitulative quality of human pluripotent stem cell (hPSC) differentiation,
we removed exogenous haematopoietic cytokines from the defined differentiation system …

Megakaryocytes (MKs) are rare polyploid cells found in the bone marrow and produce
platelets. Platelets are small cell fragments that are critical to vascular hemostasis and …

Previously, we investigated the process of megakaryocytopoiesis during ex vivo expansion
of human cord blood (CB) CD34+ cells using thrombopoietin (TPO) and found that …

Red blood cells and platelets are anucleate blood components indispensable for oxygen
delivery and hemostasis, respectively. Derivation of these blood elements from induced …

BACKGROUND Cultured megakaryocytes could prove useful in the study of human
diseases, but it is difficult to produce sufficient numbers for study. We describe and evaluate …